TY - JOUR
T1 - Competing risks in patients with primary prevention implantable cardioverter-defibrillators
T2 - Global Electrical Heterogeneity and Clinical Outcomes study
AU - Waks, Jonathan W.
AU - Haq, Kazi T.
AU - Tompkins, Christine
AU - Rogers, Albert J.
AU - Ehdaie, Ashkan
AU - Bender, Aron
AU - Minnier, Jessica
AU - Dalouk, Khidir
AU - Howell, Stacey
AU - Peiris, Achille
AU - Raitt, Merritt
AU - Narayan, Sanjiv M.
AU - Chugh, Sumeet S.
AU - Tereshchenko, Larisa G.
N1 - Funding Information:
Funding sources: American Heart Association Grant-In-Aid #17GRNT33670428 (to L.G.T.) and the National Institutes of Health (NIH) / The National Heart, Lung, and Blood Institute (NHLBI) R01HL118277 and R56HL118277 (to L.G.T.).
Publisher Copyright:
© 2021 Heart Rhythm Society
PY - 2021/6
Y1 - 2021/6
N2 - Background: Global electrical heterogeneity (GEH) is associated with sudden cardiac death in the general population. Its utility in patients with systolic heart failure who are candidates for primary prevention (PP) implantable cardioverter-defibrillators (ICDs) is unclear. Objective: The purpose of this study was to investigate whether GEH is associated with sustained ventricular tachycardia/ventricular fibrillation leading to appropriate ICD therapies in patients with heart failure and PP ICDs. Methods: We conducted a multicenter retrospective cohort study. GEH was measured by spatial ventricular gradient (SVG) direction (azimuth and elevation) and magnitude, QRS-T angle, and sum absolute QRST integral on preimplant 12-lead electrocardiograms. Survival analysis using cause-specific hazard functions compared the strength of associations with 2 competing outcomes: sustained ventricular tachycardia/ventricular fibrillation leading to appropriate ICD therapies and all-cause death without appropriate ICD therapies. Results: We analyzed 2668 patients (mean age 63 ± 12 years; 624 (23%) female; 78% white; 43% nonischemic cardiomyopathy; left ventricular ejection fraction 28% ± 11% from 6 academic medical centers). After adjustment for demographic, clinical, device, and traditional electrocardiographic characteristics, SVG elevation (hazard ratio [HR] per 1SD 1.14; 95% confidence interval [CI] 1.04–1.25; P =.004), SVG azimuth (HR per 1SD 1.12; 95% CI 1.01–1.24; P =.039), SVG magnitude (HR per 1SD 0.75; 95% CI 0.66–0.85; P <.0001), and QRS-T angle (HR per 1SD 1.21; 95% CI 1.08–1.36; P =.001) were associated with appropriate ICD therapies. Sum absolute QRST integral had different associations in infarct-related cardiomyopathy (HR 1.29; 95% CI 1.04–1.60) and nonischemic cardiomyopathy (HR 0.78; 95% CI 0.62–0.96) (Pinteraction =.022). Conclusion: In patients with PP ICDs, GEH is independently associated with appropriate ICD therapies. The SVG vector points in distinctly different directions in patients with 2 competing outcomes.
AB - Background: Global electrical heterogeneity (GEH) is associated with sudden cardiac death in the general population. Its utility in patients with systolic heart failure who are candidates for primary prevention (PP) implantable cardioverter-defibrillators (ICDs) is unclear. Objective: The purpose of this study was to investigate whether GEH is associated with sustained ventricular tachycardia/ventricular fibrillation leading to appropriate ICD therapies in patients with heart failure and PP ICDs. Methods: We conducted a multicenter retrospective cohort study. GEH was measured by spatial ventricular gradient (SVG) direction (azimuth and elevation) and magnitude, QRS-T angle, and sum absolute QRST integral on preimplant 12-lead electrocardiograms. Survival analysis using cause-specific hazard functions compared the strength of associations with 2 competing outcomes: sustained ventricular tachycardia/ventricular fibrillation leading to appropriate ICD therapies and all-cause death without appropriate ICD therapies. Results: We analyzed 2668 patients (mean age 63 ± 12 years; 624 (23%) female; 78% white; 43% nonischemic cardiomyopathy; left ventricular ejection fraction 28% ± 11% from 6 academic medical centers). After adjustment for demographic, clinical, device, and traditional electrocardiographic characteristics, SVG elevation (hazard ratio [HR] per 1SD 1.14; 95% confidence interval [CI] 1.04–1.25; P =.004), SVG azimuth (HR per 1SD 1.12; 95% CI 1.01–1.24; P =.039), SVG magnitude (HR per 1SD 0.75; 95% CI 0.66–0.85; P <.0001), and QRS-T angle (HR per 1SD 1.21; 95% CI 1.08–1.36; P =.001) were associated with appropriate ICD therapies. Sum absolute QRST integral had different associations in infarct-related cardiomyopathy (HR 1.29; 95% CI 1.04–1.60) and nonischemic cardiomyopathy (HR 0.78; 95% CI 0.62–0.96) (Pinteraction =.022). Conclusion: In patients with PP ICDs, GEH is independently associated with appropriate ICD therapies. The SVG vector points in distinctly different directions in patients with 2 competing outcomes.
KW - Competing risk
KW - Global electrical heterogeneity
KW - Heart failure
KW - Implantable cardioverter-defibrillators
KW - Ventricular tachycardia/Ventricular fibrillation
UR - http://www.scopus.com/inward/record.url?scp=85106274104&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85106274104&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2021.03.006
DO - 10.1016/j.hrthm.2021.03.006
M3 - Article
C2 - 33684549
AN - SCOPUS:85106274104
SN - 1547-5271
VL - 18
SP - 977
EP - 986
JO - Heart Rhythm
JF - Heart Rhythm
IS - 6
ER -